{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:09:55Z","timestamp":1747159795936,"version":"3.40.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejps.2018.07.056","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T02:03:05Z","timestamp":1533261785000},"page":"531-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-1399","authenticated-orcid":false,"given":"Malte Selch","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus Vestergaard","family":"Juul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-4341","authenticated-orcid":false,"given":"Mads","family":"Kreilgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie T.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrika S.H.","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.07.056_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejps.2018.07.056_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12370","article-title":"Methods for individualising factor VIII dosing in prophylaxis","volume":"93","author":"Ar","year":"2014","journal-title":"Eur. J. Haematol."},{"year":"2009","series-title":"NONMEM Users Guides (1989\u20132009)","author":"Beal","key":"10.1016\/j.ejps.2018.07.056_bb0015"},{"key":"10.1016\/j.ejps.2018.07.056_bb0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bj\u00f6rkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejps.2018.07.056_bb0025","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2018.07.056_bb0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jcrc.2009.01.009","article-title":"Simulation for clinical research trials: a theoretical outline","volume":"24","author":"Brindley","year":"2009","journal-title":"J. Crit. Care"},{"year":"1988","series-title":"Extreme Value Theory","author":"Castillo","key":"10.1016\/j.ejps.2018.07.056_bb0035"},{"key":"10.1016\/j.ejps.2018.07.056_bb0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/hae.12175","article-title":"Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients","volume":"19","author":"Ceponis","year":"2013","journal-title":"Haemophilia"},{"year":"2006","series-title":"Study Comparing On-demand Treatment With Two Prophylaxis Regimens of BeneFIX in Patients With Severe Hemophilia B","author":"ClinicalTrials.gov","key":"10.1016\/j.ejps.2018.07.056_bb0045"},{"year":"2015","series-title":"Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects","author":"ClinicalTrials.gov","key":"10.1016\/j.ejps.2018.07.056_bb0050"},{"key":"10.1016\/j.ejps.2018.07.056_bb0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1023\/A:1020930626404","article-title":"A population pharmacokinetic\u2013pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron","volume":"27","author":"Cox","year":"1999","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2018.07.056_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2516.2012.02824.x","article-title":"Clinical trial design in haemophilia","volume":"18","author":"Dimichele","year":"2012","journal-title":"Haemophilia"},{"year":"2001","series-title":"Small Clinical Trials Issues and Challenges","author":"Evans","key":"10.1016\/j.ejps.2018.07.056_bb0065"},{"key":"10.1016\/j.ejps.2018.07.056_bb0070","first-page":"s319","article-title":"Key issues in inhibitor management in patients with haemophilia","volume":"12","author":"Gomez","year":"2014","journal-title":"Blood Transfus."},{"key":"10.1016\/j.ejps.2018.07.056_bb0075","first-page":"513","article-title":"On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies","volume":"115","author":"Gompertz","year":"1825","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.ejps.2018.07.056_bb0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejps.2018.07.056_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.18","article-title":"A time to event tutorial for pharmacometricians","volume":"2","author":"Holford","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2018.07.056_bb0090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/clpt.2010.114","article-title":"Clinical trial simulation: a review","volume":"88","author":"Holford","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.07.056_bb0095","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/jth.12816","article-title":"The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight\u00ae), in patients with hemophilia A","volume":"13","author":"Jim\u00e9nez-Yuste","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2018.07.056_bb0100","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/ALN.0000000000000917","article-title":"Repeated Time-to-event analysis of consecutive analgesic events in postoperative pain","volume":"123","author":"Juul","year":"2015","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.ejps.2018.07.056_bb0105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10928-017-9522-4","article-title":"Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches","volume":"44","author":"Juul","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.07.056_bb0110","series-title":"Population Approach Group in Europe; Marseille, France, Abstract 1434","article-title":"A tutorial on visual predictive checks","author":"Karlsson","year":"2008"},{"key":"10.1016\/j.ejps.2018.07.056_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2018.07.056_bb0120","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/cc4977","article-title":"Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding","volume":"10","author":"Klitgaard","year":"2006","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejps.2018.07.056_bb0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0049124196024004001","article-title":"A comparison of poisson, negative binomial, and semiparametric mixed poisson regression models: with empirical applications to criminal careers data","volume":"24","author":"Land","year":"1996","journal-title":"Sociol. Methods Res."},{"key":"10.1016\/j.ejps.2018.07.056_bb0130","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/jth.12237","article-title":"40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors","volume":"11","author":"Ljung","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2018.07.056_bb0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198008213030803","article-title":"Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII","volume":"303","author":"Lusher","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.07.056_bb0140","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1124\/jpet.111.181636","article-title":"Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model","volume":"339","author":"Plan","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2018.07.056_bb0145","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/jth.13771","article-title":"In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients","volume":"15","author":"Preijers","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2018.07.056_bb0150","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2307\/2533673","article-title":"A general framework for random effects survival analysis in the Cox proportional hazards setting","volume":"54","author":"Sargent","year":"1998","journal-title":"Biometrics"},{"key":"10.1016\/j.ejps.2018.07.056_bb0155","first-page":"555","article-title":"Anti-hemophilic factor (recombinant), plasma\/albumin-free method (octocog-alpha; ADVATE(\u00ae)) in the management of hemophilia A","volume":"3","author":"Shapiro","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejps.2018.07.056_bb0160","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10928-009-9131-y","article-title":"Modelling overdispersion and Markovian features in count data","volume":"36","author":"Troc\u00f3niz","year":"2009","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.07.056_bb0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","article-title":"Assessment of actual significance levels for covariate effects in NONMEM","volume":"28","author":"W\u00e4hlby","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.07.056_bb0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020254823597","article-title":"Assessment of type I error rates for the statistical sub-model in NONMEM","volume":"29","author":"W\u00e4hlby","year":"2002","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.07.056_bb0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/B:JOPA.0000029489.97168.a9","article-title":"Evaluation of type I error rates when modeling ordered categorical data in NONMEM","volume":"31","author":"W\u00e4hlby","year":"2004","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.07.056_bb0180","first-page":"276","article-title":"On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications","volume":"109","author":"Wellek","year":"2012","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"10.1016\/j.ejps.2018.07.056_bb0190","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2017","journal-title":"Clin. Pharmacokinet."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718303610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718303610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T22:22:34Z","timestamp":1720477354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718303610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":37,"alternative-id":["S0928098718303610"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.07.056","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}